In September last year, the USD three billion drug maker said its US
subsidiary entered into an agreement to acquire commercial operations
and three manufacturing facilities in America from Sandoz Inc, USA, a
Novartis Division, for USD 900 million.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-aims-to-become-debt-free-in-3-years-sans-sandoz-deal/articleshow/72206881.cms
No comments:
Post a Comment